Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's drugs
Biotech
Vivoryon Alzheimer’s drug fails phase 2 trial, crashing stock
Vivoryon Therapeutic’s lead asset missed all endpoints in a phase 2 trial, sending the company’s stock plunging 90%.
James Waldron
Mar 4, 2024 8:13am
Silo’s Alzheimer's ketamine med reduces dementia signs in mice
Jan 25, 2024 12:09pm
'The Top Line': Unraveling Alzheimer's disease treatments
Oct 13, 2023 6:00am
Lilly reveals how Alzheimer's drug shapes up against Leqembi
Jul 17, 2023 10:15am
Prothena teams with Walgreens to accelerate Alzheimer's trial
Apr 13, 2023 9:55am
Eisai rocked by 2nd death ahead of Alzheimer’s data reveal
Nov 28, 2022 10:53am
